WFMZ-TV

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...
Taiwan News

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on ...

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE)-- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by ...
Reuters

China approves market launch of brain-computer interface medical device in world first

HONG KONG, March 13 (Reuters) - China's drug regulator said on Friday that it has given the nod for a brain-computer interface (BCI) system that helps restore hand-movement ability to be sold, the ...